Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Life Sciences
Reports from Landspitali University highlight recent research in life sciences
April 15th, 2009
According to a study from Reykjavik, Iceland, "IC31((R)) is a novel adjuvant which combines the immunostimulatory effects of an 11-mer antibacterial peptide (KLKL5KLK) and a synthetic oligodeoxynucleotide (ODN1a) which is a Toll-like receptor 9 agonist without containing cytosine phosphate guanine (CpG) motifs. The effects of IC31((R)) on neonatal immune response to vaccination have not been reported." "Neonatal mice were immunized once or twice with a Streptococcus pneumoniae serotype 1 polysaccharide conjugate containing Tetanus Toxoid (Pnc1-TT) carrier protein, with or without IC31((R)) or CpG-ODN. IC31((R)) significantly enhanced IgG1, IgG2a and IgG2b antibodies...
Source: Vaccine Weekly (2009-04-15)
|
